Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) posted its quarterly earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports.

Immix Biopharma Stock Performance

IMMX stock traded down $0.09 during midday trading on Friday, reaching $7.98. 429,396 shares of the company were exchanged, compared to its average volume of 1,313,020. The company has a market cap of $570.89 million, a price-to-earnings ratio of -9.10 and a beta of 0.29. Immix Biopharma has a 1-year low of $3.56 and a 1-year high of $15.10. The stock’s 50-day simple moving average is $9.94 and its 200 day simple moving average is $9.57.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on IMMX shares. HC Wainwright raised their price objective on shares of Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 10th. Needham & Company LLC boosted their target price on shares of Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th. Morgan Stanley reissued an “overweight” rating on shares of Immix Biopharma in a report on Tuesday, October 20th. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a research note on Wednesday, September 30th. Finally, Mizuho set a $23.00 price target on Immix Biopharma in a research note on Thursday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immix Biopharma currently has an average rating of “Moderate Buy” and an average price target of $23.86.

Immix Biopharma Company Profile

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.